Company news
Satellos Bioscience Inc (TSX:MSCL) news
Satellos Bioscience Inc news releases on 6ix. Latest, Oct 5, 2026: Satellos Granted Composition of Matter Patent for Forazapadin
Press releases & updates
Satellos Granted Composition of Matter Patent for Forazapadin
October 5, 2026
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
September 30, 2026
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
September 24, 2026
Satellos to Present at the 31st Annual Congress of the World Muscle Society
September 15, 2026
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
September 9, 2026
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
August 13, 2026
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
July 8, 2026
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
June 29, 2026
Satellos to Present Clinical Program Updates at ICNMD 2026
June 25, 2026
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
June 17, 2026
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
May 15, 2026
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 9, 2026
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
March 27, 2026
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
March 10, 2026
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
February 24, 2026
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
February 18, 2026
Satellos to Participate in Upcoming Investor Conferences
February 17, 2026
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
February 12, 2026
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 10, 2026
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares
February 9, 2026
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
February 9, 2026
Canadian Investment Regulatory Organization Trade Resumption - MSCL
February 6, 2026
Canadian Investment Regulatory Organization Trading Halt - MSCL
February 6, 2026
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
February 6, 2026
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
February 5, 2026
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
January 29, 2026
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
January 28, 2026
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
December 9, 2025
Satellos to Participate in December Investor Conferences
November 25, 2025
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
November 18, 2025
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
November 14, 2025
Satellos to Participate in November Investor Conferences
October 30, 2025
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
October 21, 2025
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
October 10, 2025
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
September 29, 2025
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
September 22, 2025
Sitryx appoints Adam Mostafa as Chief Financial Officer
September 8, 2025
Satellos to Participate in Four September Institutional and Retail Investor Conferences
August 21, 2025
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
August 13, 2025
Satellos to Present at Canaccord Genuity's 45th Annual Growth Conference
August 5, 2025
Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
August 5, 2025
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
July 16, 2025
Satellos Bioscience Shareholders Elect Two New Board Members
June 18, 2025
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
June 18, 2025
Satellos Bioscience to Participate in PPMD's Annual Conference in Las Vegas
June 16, 2025
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
June 16, 2025
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
May 22, 2025
Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants
May 20, 2025
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
May 13, 2025
Satellos to Present at the CureDuchenne FUTURES National Conference
May 7, 2025